Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling-Reference-Cited by-同舟云学术

Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling

Published:2018-06-07 Issue:11 Volume:84 Page:2483-2487
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Liu Zheng¹²³^ORCID,Martin Jennifer H.¹²^ORCID

Affiliation:

1. School of Medicine and Public HealthUniversity of Newcastle, Hunter Medical Research Institute, Kookaburra Circuit NSW 2305 Australia

2. The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) New Lambton Heights NSW 2305 Australia

3. Clinical Pharmacology, Department of MedicineThe Royal Children's Hospital Melbourne Australia

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13635

Reference44 articles.

1. Australian Government Health Department. Medicinal cannabis – guidance documents. Available athttps://www.tga.gov.au/access‐medicinal‐cannabis‐products(last accessed 29 May 2018).

2. Review on clinical studies with cannabis and cannabinoids 2005–2009;Hazekamp A;Cannabinoids,2010

3. Medicinal Use of Cannabis: History and Current Status

4. Medical Marijuana Use in Oncology

5. Modulating the endocannabinoid system in human health and disease - successes and failures

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CFPD-PK simulation of inhaled Delta-9-tetrahydrocannabinol aerosol dynamics: Transport, deposition, and translocation in a mouth-to-G10 subject-specific human airway;Journal of Aerosol Science;2024-03

2. Patient views regarding cannabis use in chronic kidney disease and kidney failure: a survey study;Nephrology Dialysis Transplantation;2022-07-26

3. Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development;Cannabis and Cannabinoid Research;2022-04-19

4. Re: “Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial” by Crippa et al.;Cannabis and Cannabinoid Research;2022-04-01

5. Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II);Pain;2022-01-24